Injektion von Botulinum Toxin in den Pylorus zur Behandlung von Chronic Upper Gastrointestinal Symptoms bei Diabetic Patients mit verzögerter Gastric Emptying

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-004217-42-AT

Enrollment

140

Registered

2005-03-22

Start date

2005-04-26

Completion date

Unknown

Last updated

2015-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

Trade Name: Botox Pharmaceutical Form: Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Gastroenteral use Trade Name: Dysport Pharmaceutical Form: Ph

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetic gastroparesis Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: no diabetic gastroparesis

Design outcomes

Primary

Measure	Time frame
Main Objective: Treatment of diabetic gastroparesis;Secondary Objective: ;Primary end point(s): 3 months after BTxA injection	—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026